Log in
LON:GWP

326553 (GWP.L) Share Forecast, Price & News

Add
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume2.32 million shs
Average Volume956,721 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company's lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD). The Company offers Sativex (nabiximols), which is indicated for the treatment of spasticity due to multiple sclerosis (MS). The Company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. The Commercial segment distributes and sells the Company's commercial products. The Sativex Research and Development segment seeks to maximize the potential of Sativex through the development of new indications. The Pipeline Research and Development segment seeks to develop cannabinoid medications other than Sativex across a range of therapeutic areas using its cannabinoid technology platform.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.62 out of 5 stars

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
CUSIPN/A
CIKN/A
Phone+44-1223-266800
EmployeesN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable
30 days | 90 days | 365 days | Advanced Chart

Receive GWP News and Ratings via Email

Sign-up to receive the latest news and ratings for GWP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











326553 (GWP.L) (LON:GWP) Frequently Asked Questions

What other stocks do shareholders of 326553 (GWP.L) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other 326553 (GWP.L) investors own include GW Pharmaceuticals (GWPH), Canopy Growth (CGC), Aurora Cannabis (ACB), Alibaba Group (BABA), Cara Therapeutics (CARA), Cronos Group (CRON), Immunomedics (IMMU), Ceragon Networks (CRNT), Nokia (NOK) and NVIDIA (NVDA).

Who are 326553 (GWP.L)'s key executives?

326553 (GWP.L)'s management team includes the following people:
  • Geoffrey W. Guy, Executive Chairman of the Board
  • Justin Gover, Chief Executive Officer, Director
  • Adam David George, Chief Financial Officer, Company Secretary, Director
  • Christopher John Tovey, Chief Operating Officer, Executive Director
  • Julian S. Gangolli, Executive Director
  • James Julian Noble, Non-Executive Deputy Chairman of the Board, Senior Independent Director
  • Cabot Brown, Non-Executive Independent Director
  • Thomas Gerard Lynch, Non-Executive Independent Director
  • Catherine J. Mackey Ph.D., Non-Executive Independent Director
  • Alicia Secor, Non-Executive Independent Director

What is 326553 (GWP.L)'s stock symbol?

326553 (GWP.L) trades on the London Stock Exchange (LON) under the ticker symbol "GWP."

How do I buy shares of 326553 (GWP.L)?

Shares of GWP and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is 326553 (GWP.L)'s official website?

The official website for 326553 (GWP.L) is www.gwpharm.com.

How can I contact 326553 (GWP.L)?

326553 (GWP.L)'s mailing address is Sovereign House, Vision Park, CAMBRIDGE, 00000, United Kingdom. The biopharmaceutical company can be reached via phone at +44-1223-266800.

This page was last updated on 10/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.